Get the Stockscreener App
29.01
8.04%
2.16
After Hours:
29.03
0.02
+0.07%
Beam Therapeutics Inc stock is traded at $29.01, with a volume of 2.66M.
It is up +8.04% in the last 24 hours and up +18.46% over the past month.
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.
See More
Previous Close:
$26.85
Open:
$26.9
24h Volume:
2.66M
Relative Volume:
2.43
Market Cap:
$2.40B
Revenue:
$352.57M
Net Income/Loss:
$-143.01M
P/E Ratio:
-6.4324
EPS:
-4.51
Net Cash Flow:
$-153.40M
1W Performance:
+3.87%
1M Performance:
+18.46%
6M Performance:
+25.91%
1Y Performance:
+4.99%
1-Day Range:
$26.73
$29.20
1-Week Range:
$24.96
$29.53
52-Week Range:
$20.84
$49.50
Beam Therapeutics Inc Stock (BEAM) Company Profile
Name
Beam Therapeutics Inc
Sector
Industry
Phone
857-327-8775
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
29.01 | 2.40B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jul-23-24 | Initiated | H.C. Wainwright | Buy |
| Jan-29-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-08-23 | Downgrade | Jefferies | Buy → Hold |
| Oct-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-20-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-13-22 | Initiated | Citigroup | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Jan-05-22 | Initiated | Guggenheim | Buy |
| Oct-19-21 | Initiated | SVB Leerink | Outperform |
| Sep-24-21 | Resumed | Stifel | Buy |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Redburn | Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-16-21 | Initiated | Wells Fargo | Overweight |
| Jan-29-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-21 | Initiated | Stifel | Hold |
| Aug-05-20 | Initiated | William Blair | Outperform |
| Mar-02-20 | Initiated | Barclays | Overweight |
| Mar-02-20 | Initiated | JP Morgan | Overweight |
| Mar-02-20 | Initiated | Jefferies | Buy |
| Mar-02-20 | Initiated | Wedbush | Outperform |
View All
Beam Therapeutics Inc Stock (BEAM) Latest News
Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation - Simply Wall St
Comprehensive Market Analysis of Latest Published 9 Rare Genetic Disorders Reports | DelveInsight - GlobeNewswire Inc.
Beam Therapeutics (BEAM) Stock Dips Amid Biotech Sector Decline - GuruFocus.com
Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Beam Therapeutics CEO to Present at J.P. Morgan Healthcare Conference: Precision Gene Editing Spotlight - StockTitan
State Street Corp Purchases 437,402 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) Sees Large Decline in Short Interest - MarketBeat
Beam Therapeutics' SWOT analysis: base editing pioneer faces competitive gene therapy market - Investing.com
Beam Therapeutics' SWOT analysis: base editing pioneer faces competitive gene therapy market By Investing.com - Investing.com South Africa
Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains - AOL
Brokers Issue Forecasts for BEAM FY2024 Earnings - MarketBeat
Beam Therapeutics announces new data from BEACON Phase 1/2 trial of BEAM-101 - MSN
Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up - MSN
Why Beam Therapeutics (BEAM) Is the Worst ARK Stock to Buy According to Short Sellers - MSN
Beam Therapeutics (NASDAQ:BEAM) Rating Increased to Hold at Cantor Fitzgerald - MarketBeat
10 Worst ARK Stocks To Buy According to Short Sellers - Insider Monkey
Beam Therapeutics shares hold Outperform amid clinical data By Investing.com - Investing.com Canada
Beam Therapeutics shares hold Outperform amid clinical data - Investing.com
Beam Therapeutics Advances BEAM-101 Therapy for Sickle Cell - TipRanks
ASH: Beam’s Base Editor Efficacy In Sickle Cell Disease Holds Up - News & Insights
Beam Therapeutics Achieves Breakthrough in Sickle Cell Treatment with Promising ESCAPE Platform Data - StockTitan
Beam Therapeutics Presents New Non-human Primate (NHP) Data - GlobeNewswire
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for - The Bakersfield Californian
Charles Schwab Investment Management Inc. Boosts Stake in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Stock Price Up 8.6%Here's Why - MarketBeat
BEAMBeam Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting - The Manila Times
Beam Therapeutics Announces New Data from BEACON Phase 1/2 - GlobeNewswire
Beam Therapeutics Reports Breakthrough Clinical Data for Sickle Cell Gene Therapy BEAM-101 - StockTitan
20,800 Shares in Beam Therapeutics Inc. (NASDAQ:BEAM) Acquired by Polar Asset Management Partners Inc. - MarketBeat
Beam Therapeutics Inc. Appoints Sravan K. Emany as Chief Financial Officer, Effective December 19, 2024 - Marketscreener.com
Beam Therapeutics Names Sravan K. Emany as CFO - TipRanks
Beam Therapeutics names Sravan K. Emany as new CFO - Investing.com
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer - The Manila Times
Beam Therapeutics Names Former Ironwood CFO & Banking Veteran Sravan Emany as New Finance Chief - StockTitan
Tom Jede - The Business Journals
Why Is Beam Therapeutics (BEAM) Down 2.3% Since Last Earnings Report? - Yahoo Finance
Redmile Group LLC Has $39.47 Million Stake in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics adds Merck executive to board By Investing.com - Investing.com Canada
Erste Asset Management GmbH Makes New $544,000 Investment in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Sold by Fmr LLC - MarketBeat
Beam Therapeutics Inc. Announces the Appointment of Chirfi Guindo to Its Board of Directors - Marketscreener.com
Beam Therapeutics adds Merck executive to board - Investing.com
Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader - The Manila Times
Beam Therapeutics Expands its Board of Directors with - GlobeNewswire
Beam Therapeutics Strengthens Board with Merck's Chief Marketing Officer Chirfi Guindo - StockTitan
Beam Therapeutics Breaks Below 200-Day Moving AverageNotable for BEAM - Nasdaq
Walleye Capital LLC Raises Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
(BEAM) Trading Report - Stock Traders Daily
20,892 Shares in Beam Therapeutics Inc. (NASDAQ:BEAM) Acquired by Intech Investment Management LLC - MarketBeat
Beam Therapeutics Inc Stock (BEAM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Beam Therapeutics Inc Stock (BEAM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ciaramella Giuseppe | President |
Nov 06 '24 |
Sale |
26.36 |
51,110 |
1,347,050 |
109,150 |
| Ciaramella Giuseppe | President |
Oct 14 '24 |
Option Exercise |
2.00 |
41,754 |
83,594 |
211,370 |
| Ciaramella Giuseppe | President |
Oct 14 '24 |
Sale |
26.27 |
51,110 |
1,342,752 |
160,260 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):